|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Ariad Pharmaceuticals Inc., of Cambridge, Mass., has filed a claim against Amgen Inc., of Thousand Oaks, Calif., and Wyeth Pharmaceuticals, of Madison, N.J., alleging infringement of the U.S. patent covering methods of treating human disease by regulating NF-(kappa)B cell-signaling activity. The claim is in response to a lawsuit filed by Amgen against Ariad in the U.S. District Court in Delaware in April 2006. That suit sought a judgment that the claims of U.S. Patent No. 6,410,516 (called the '516 Patent) are invalid and that Amgen has not infringed any of the claims of the patent based on activities related to Enbrel (etanercept) and Kineret (anakinra). Enbrel is a ...